Loading…
Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece
The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides wi...
Saved in:
| Published in: | Journal of chemotherapy (Florence) 2012-08, Vol.24 (4), p.191-194 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c482t-736159962496d1fa01c977fa584085dfc2736c9dfda56972b7e9f61a652303ee3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c482t-736159962496d1fa01c977fa584085dfc2736c9dfda56972b7e9f61a652303ee3 |
| container_end_page | 194 |
| container_issue | 4 |
| container_start_page | 191 |
| container_title | Journal of chemotherapy (Florence) |
| container_volume | 24 |
| creator | Galani, Irene Souli, Maria Daikos, George L Chrysouli, Zoi Poulakou, Garyphalia Psichogiou, Mina Panagea, Theofano Argyropoulou, Athina Stefanou, Ioanna Plakias, George Giamarellou, Helen Petrikkos, George |
| description | The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC
50
/MIC
90
to tobramycin, amikacin and gentamicin being 32/>32, 32/>32 and 4/>8 μg/ml, respectively. ACHN-490 retained activity (MICs⩽4 μg/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC
50
and MIC
90
of 1 and 2 μg/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens. |
| doi_str_mv | 10.1179/1973947812Y.0000000015 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_23040681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2767404261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-736159962496d1fa01c977fa584085dfc2736c9dfda56972b7e9f61a652303ee3</originalsourceid><addsrcrecordid>eNqFkV1rFDEUhgdRbKn9CyUgQoWdNZnJZCY3wrCurVg_EAW9CmczSTclk6zJTGX9H_5fM-72Q2_MzQmc530557xZdkLwnJCavyC8LjmtG1J8m-P9I9WD7HBq5FPnYfqTAucY868H2XGMVxPDiqRjj7ODosQUs4YcZr9aOZhrM2yR1-ijhZ--N9I4dNouzt_nlOPnCC7BuDigd68-IWmNMxIsMtFbGFScZG-tWkWjrAW0cWrsvTOgZmgZ5VoFI9cGkPTWzBC4Di3doIJfgUwFxc1mjnTwPWqHtXJxhs6CUlI9yR5psFEd7-tR9uX18vPiPL_4cPZm0V7kkjbFkNclIxXnrKCcdUQDJpLXtYaqobipOi3TvkzyTndQMV4Xq1pxzQiwKh2gVKo8yl7ufDfjqledVG4IYMUmmB7CVngw4u-OM2tx6a9FSTFpSpYMTvcGwX8fVRxEb6KcTuGUH6MgmFe0Kjib0Kf_oFd-DC6tlyha8rpJGSaK7SgZfIxB6dthCBZT-OJe-OIu_CQ8ub_Krewm6gQ82wMQU4I6gJMm3nGMNJT_MWp3nHHahx5--GA7McDW-nAjKv8zzG9Plsql</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1043978015</pqid></control><display><type>article</type><title>Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Galani, Irene ; Souli, Maria ; Daikos, George L ; Chrysouli, Zoi ; Poulakou, Garyphalia ; Psichogiou, Mina ; Panagea, Theofano ; Argyropoulou, Athina ; Stefanou, Ioanna ; Plakias, George ; Giamarellou, Helen ; Petrikkos, George</creator><creatorcontrib>Galani, Irene ; Souli, Maria ; Daikos, George L ; Chrysouli, Zoi ; Poulakou, Garyphalia ; Psichogiou, Mina ; Panagea, Theofano ; Argyropoulou, Athina ; Stefanou, Ioanna ; Plakias, George ; Giamarellou, Helen ; Petrikkos, George</creatorcontrib><description>The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC
50
/MIC
90
to tobramycin, amikacin and gentamicin being 32/>32, 32/>32 and 4/>8 μg/ml, respectively. ACHN-490 retained activity (MICs⩽4 μg/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC
50
and MIC
90
of 1 and 2 μg/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens.</description><identifier>ISSN: 1120-009X</identifier><identifier>EISSN: 1973-9478</identifier><identifier>DOI: 10.1179/1973947812Y.0000000015</identifier><identifier>PMID: 23040681</identifier><language>eng</language><publisher>Firenze: Taylor & Francis</publisher><subject>Amikacin - pharmacology ; Aminoglycosides ; Anti-Bacterial Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobial Chemotherapy ; Biological and medical sciences ; Drug Resistance, Multiple, Bacterial ; Enterobacter - drug effects ; Enterobacter - isolation & purification ; Enterobacter - metabolism ; Enterobacteriaceae Infections - microbiology ; Escherichia coli - drug effects ; Escherichia coli - isolation & purification ; Escherichia coli - metabolism ; Escherichia coli Infections - microbiology ; Gentamicins - pharmacology ; Greece ; Humans ; Klebsiella Infections - microbiology ; Klebsiella pneumoniae - drug effects ; Klebsiella pneumoniae - isolation & purification ; Klebsiella pneumoniae - metabolism ; KPC ; Medical sciences ; Microbial Sensitivity Tests ; Multidrug resistant ; Pharmacology. Drug treatments ; Sisomicin - analogs & derivatives ; Sisomicin - pharmacology ; Tertiary Care Centers ; Tobramycin - pharmacology ; VIM</subject><ispartof>Journal of chemotherapy (Florence), 2012-08, Vol.24 (4), p.191-194</ispartof><rights>2012 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Maney Publishing Aug 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-736159962496d1fa01c977fa584085dfc2736c9dfda56972b7e9f61a652303ee3</citedby><cites>FETCH-LOGICAL-c482t-736159962496d1fa01c977fa584085dfc2736c9dfda56972b7e9f61a652303ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26184915$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23040681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galani, Irene</creatorcontrib><creatorcontrib>Souli, Maria</creatorcontrib><creatorcontrib>Daikos, George L</creatorcontrib><creatorcontrib>Chrysouli, Zoi</creatorcontrib><creatorcontrib>Poulakou, Garyphalia</creatorcontrib><creatorcontrib>Psichogiou, Mina</creatorcontrib><creatorcontrib>Panagea, Theofano</creatorcontrib><creatorcontrib>Argyropoulou, Athina</creatorcontrib><creatorcontrib>Stefanou, Ioanna</creatorcontrib><creatorcontrib>Plakias, George</creatorcontrib><creatorcontrib>Giamarellou, Helen</creatorcontrib><creatorcontrib>Petrikkos, George</creatorcontrib><title>Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece</title><title>Journal of chemotherapy (Florence)</title><addtitle>J Chemother</addtitle><description>The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC
50
/MIC
90
to tobramycin, amikacin and gentamicin being 32/>32, 32/>32 and 4/>8 μg/ml, respectively. ACHN-490 retained activity (MICs⩽4 μg/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC
50
and MIC
90
of 1 and 2 μg/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens.</description><subject>Amikacin - pharmacology</subject><subject>Aminoglycosides</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobial Chemotherapy</subject><subject>Biological and medical sciences</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Enterobacter - drug effects</subject><subject>Enterobacter - isolation & purification</subject><subject>Enterobacter - metabolism</subject><subject>Enterobacteriaceae Infections - microbiology</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - isolation & purification</subject><subject>Escherichia coli - metabolism</subject><subject>Escherichia coli Infections - microbiology</subject><subject>Gentamicins - pharmacology</subject><subject>Greece</subject><subject>Humans</subject><subject>Klebsiella Infections - microbiology</subject><subject>Klebsiella pneumoniae - drug effects</subject><subject>Klebsiella pneumoniae - isolation & purification</subject><subject>Klebsiella pneumoniae - metabolism</subject><subject>KPC</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Multidrug resistant</subject><subject>Pharmacology. Drug treatments</subject><subject>Sisomicin - analogs & derivatives</subject><subject>Sisomicin - pharmacology</subject><subject>Tertiary Care Centers</subject><subject>Tobramycin - pharmacology</subject><subject>VIM</subject><issn>1120-009X</issn><issn>1973-9478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNqFkV1rFDEUhgdRbKn9CyUgQoWdNZnJZCY3wrCurVg_EAW9CmczSTclk6zJTGX9H_5fM-72Q2_MzQmc530557xZdkLwnJCavyC8LjmtG1J8m-P9I9WD7HBq5FPnYfqTAucY868H2XGMVxPDiqRjj7ODosQUs4YcZr9aOZhrM2yR1-ijhZ--N9I4dNouzt_nlOPnCC7BuDigd68-IWmNMxIsMtFbGFScZG-tWkWjrAW0cWrsvTOgZmgZ5VoFI9cGkPTWzBC4Di3doIJfgUwFxc1mjnTwPWqHtXJxhs6CUlI9yR5psFEd7-tR9uX18vPiPL_4cPZm0V7kkjbFkNclIxXnrKCcdUQDJpLXtYaqobipOi3TvkzyTndQMV4Xq1pxzQiwKh2gVKo8yl7ufDfjqledVG4IYMUmmB7CVngw4u-OM2tx6a9FSTFpSpYMTvcGwX8fVRxEb6KcTuGUH6MgmFe0Kjib0Kf_oFd-DC6tlyha8rpJGSaK7SgZfIxB6dthCBZT-OJe-OIu_CQ8ub_Krewm6gQ82wMQU4I6gJMm3nGMNJT_MWp3nHHahx5--GA7McDW-nAjKv8zzG9Plsql</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Galani, Irene</creator><creator>Souli, Maria</creator><creator>Daikos, George L</creator><creator>Chrysouli, Zoi</creator><creator>Poulakou, Garyphalia</creator><creator>Psichogiou, Mina</creator><creator>Panagea, Theofano</creator><creator>Argyropoulou, Athina</creator><creator>Stefanou, Ioanna</creator><creator>Plakias, George</creator><creator>Giamarellou, Helen</creator><creator>Petrikkos, George</creator><general>Taylor & Francis</general><general>EIFT</general><general>Taylor & Francis Ltd</general><general>Maney Publishing</general><scope>0YH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120801</creationdate><title>Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece</title><author>Galani, Irene ; Souli, Maria ; Daikos, George L ; Chrysouli, Zoi ; Poulakou, Garyphalia ; Psichogiou, Mina ; Panagea, Theofano ; Argyropoulou, Athina ; Stefanou, Ioanna ; Plakias, George ; Giamarellou, Helen ; Petrikkos, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-736159962496d1fa01c977fa584085dfc2736c9dfda56972b7e9f61a652303ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Amikacin - pharmacology</topic><topic>Aminoglycosides</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobial Chemotherapy</topic><topic>Biological and medical sciences</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Enterobacter - drug effects</topic><topic>Enterobacter - isolation & purification</topic><topic>Enterobacter - metabolism</topic><topic>Enterobacteriaceae Infections - microbiology</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - isolation & purification</topic><topic>Escherichia coli - metabolism</topic><topic>Escherichia coli Infections - microbiology</topic><topic>Gentamicins - pharmacology</topic><topic>Greece</topic><topic>Humans</topic><topic>Klebsiella Infections - microbiology</topic><topic>Klebsiella pneumoniae - drug effects</topic><topic>Klebsiella pneumoniae - isolation & purification</topic><topic>Klebsiella pneumoniae - metabolism</topic><topic>KPC</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Multidrug resistant</topic><topic>Pharmacology. Drug treatments</topic><topic>Sisomicin - analogs & derivatives</topic><topic>Sisomicin - pharmacology</topic><topic>Tertiary Care Centers</topic><topic>Tobramycin - pharmacology</topic><topic>VIM</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galani, Irene</creatorcontrib><creatorcontrib>Souli, Maria</creatorcontrib><creatorcontrib>Daikos, George L</creatorcontrib><creatorcontrib>Chrysouli, Zoi</creatorcontrib><creatorcontrib>Poulakou, Garyphalia</creatorcontrib><creatorcontrib>Psichogiou, Mina</creatorcontrib><creatorcontrib>Panagea, Theofano</creatorcontrib><creatorcontrib>Argyropoulou, Athina</creatorcontrib><creatorcontrib>Stefanou, Ioanna</creatorcontrib><creatorcontrib>Plakias, George</creatorcontrib><creatorcontrib>Giamarellou, Helen</creatorcontrib><creatorcontrib>Petrikkos, George</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of chemotherapy (Florence)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galani, Irene</au><au>Souli, Maria</au><au>Daikos, George L</au><au>Chrysouli, Zoi</au><au>Poulakou, Garyphalia</au><au>Psichogiou, Mina</au><au>Panagea, Theofano</au><au>Argyropoulou, Athina</au><au>Stefanou, Ioanna</au><au>Plakias, George</au><au>Giamarellou, Helen</au><au>Petrikkos, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece</atitle><jtitle>Journal of chemotherapy (Florence)</jtitle><addtitle>J Chemother</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>24</volume><issue>4</issue><spage>191</spage><epage>194</epage><pages>191-194</pages><issn>1120-009X</issn><eissn>1973-9478</eissn><abstract>The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC
50
/MIC
90
to tobramycin, amikacin and gentamicin being 32/>32, 32/>32 and 4/>8 μg/ml, respectively. ACHN-490 retained activity (MICs⩽4 μg/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC
50
and MIC
90
of 1 and 2 μg/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens.</abstract><cop>Firenze</cop><pub>Taylor & Francis</pub><pmid>23040681</pmid><doi>10.1179/1973947812Y.0000000015</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1120-009X |
| ispartof | Journal of chemotherapy (Florence), 2012-08, Vol.24 (4), p.191-194 |
| issn | 1120-009X 1973-9478 |
| language | eng |
| recordid | cdi_pubmed_primary_23040681 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Amikacin - pharmacology Aminoglycosides Anti-Bacterial Agents - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Antimicrobial Chemotherapy Biological and medical sciences Drug Resistance, Multiple, Bacterial Enterobacter - drug effects Enterobacter - isolation & purification Enterobacter - metabolism Enterobacteriaceae Infections - microbiology Escherichia coli - drug effects Escherichia coli - isolation & purification Escherichia coli - metabolism Escherichia coli Infections - microbiology Gentamicins - pharmacology Greece Humans Klebsiella Infections - microbiology Klebsiella pneumoniae - drug effects Klebsiella pneumoniae - isolation & purification Klebsiella pneumoniae - metabolism KPC Medical sciences Microbial Sensitivity Tests Multidrug resistant Pharmacology. Drug treatments Sisomicin - analogs & derivatives Sisomicin - pharmacology Tertiary Care Centers Tobramycin - pharmacology VIM |
| title | Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A53%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activity%20of%20Plazomicin%20(ACHN-490)%20against%20MDR%20clinical%20isolates%20of%20Klebsiella%20pneumoniae,%20Escherichia%20coli,%20and%20Enterobacter%20spp.%20from%20Athens,%20Greece&rft.jtitle=Journal%20of%20chemotherapy%20(Florence)&rft.au=Galani,%20Irene&rft.date=2012-08-01&rft.volume=24&rft.issue=4&rft.spage=191&rft.epage=194&rft.pages=191-194&rft.issn=1120-009X&rft.eissn=1973-9478&rft_id=info:doi/10.1179/1973947812Y.0000000015&rft_dat=%3Cproquest_pubme%3E2767404261%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c482t-736159962496d1fa01c977fa584085dfc2736c9dfda56972b7e9f61a652303ee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1043978015&rft_id=info:pmid/23040681&rfr_iscdi=true |